Posted Today Yale researchers made an unexpected discovery—turncoat T cells that help a tumor evade other cancer-fighting immune T cells—in a study of patients living with advanced melanomathat was published in Nature Immunology. Melanoma cells – artistic impression. Image credit: Gemini / Alius Noreika The study by Yale Cancer Center (YCC) researchers at Yale School of Medicine (YSM)...
Tag: <span>MELANOMA</span>
Post
Tumor characteristics found to differ for melanomas in children, teens and young adults
by Elana Gotkine Tumor characteristics differ significantly among pediatric and adolescent and young adult (AYA) patients with melanoma, with decreasing incidence rates seen among young patients with cutaneous melanoma, according to a study published online Nov. 15 in the Journal of the American Academy of Dermatology. Bianca E. Ituarte, from the University of Nebraska Medical Center in Omaha,...
Post
Cutaneous malignant melanoma incidence increasing among the elderly
by Elana Gotkine From 1987 to 2016, there was a considerable increase in the incidence of cutaneous malignant melanoma (CMM) among the elderly in the United States, according to a study published online Oct. 28 in Cancer Screening and Prevention. ADVERTISING Ruofei Du, Ph.D., from Shaanxi University of Chinese Medicine in Xianyang, and colleagues examined CMM incidence trends...
Post
Tumor-specific antibodies able to detect melanoma in its earliest stages, new study shows
September 25, 2024 by European Academy of Dermatology and Venereology Innovative research has unveiled promising advancements in melanoma detection, which could significantly enhance diagnosis and prognosis by identifying the disease at its earliest, most treatable stages. This new method, presented today at the European Academy of Dermatology and Venereology (EADV) Congress 2024, uses tumor-specific profiling...
Post
Cell line models identify cause of melanoma with drug resistance
AMD1 inactivation sensitizes BRAF mutant melanoma to vemurafenib. Credit: Molecular Cancer (2024). DOI: 10.1186/s12943-024-02031-w Melanoma is a type of cancer that originates from melanocytes, the cells responsible for producing skin pigment, and is known as the most lethal form of skin cancer due to its high rates of metastasis and recurrence. With the global trend of aging...
Post
Prognostic and therapeutic insights into MIF, DDT, and CD74 in melanoma
July 26, 2024 by Impact Journals LLC Tumor infiltrating immune cell profiling according to high (cyan) and low (salmon) CD74:MIF levels (A) and CD74:DDT levels (B) using TIMER2.0 deconvolution analysis. Credit: 2024 Valdez et al.A new research paper was published in Oncotarget entitled, “Prognostic and therapeutic insights into MIF, DDT, and CD74 in melanoma.” Macrophage...
Post
HOW MELANOMA BECOMES RESISTANT TO TREATMENT
JULY 1ST, 2024 POSTED BY U. ZURICH UNIVERSITY UNIVERSITY OF ZURICHResearchers have discovered the mechanism behind melanoma’s resistance to treatment. These findings could pave the way for more effective therapies. Malignant melanoma is one of the most aggressive types of cancer. Despite recent progress in effective therapies, the tumors of many patients are either resistant...
Post
New study reveals mechanism of cell death in melanoma cells by cannabis extract
by Charles Darwin University Graphical abstract. Credit: Cells (2024). DOI: 10.3390/cells13030268A cannabis extract has shown positive results in slowing down melanoma cell growth and increasing cell death rates, a new in-vitro study finds. Researchers from Charles Darwin University (CDU) and RMIT investigated programmed cell death caused by a specific cannabis extract (cannabinoid PHEC-66) from the cannabis...
Post
Researchers identify critical pathway responsible for melanoma drug resistance
Findings may have far-reaching implications for the responsiveness of cancers to epigenetic therapies Peer-Reviewed Publication BOSTON UNIVERSITY SCHOOL OF MEDICINE (Boston)—One of the major challenges in cancer research and clinical care is understanding the molecular basis for therapeutic resistance as a major cause of long term treatment failures. In cases of melanoma, the main targeted...
Post
Coming Soon: The First mRNA Vaccine for Melanoma?
Moderna and Merck have presented promising results from their phase 2b clinical trial that investigated a combination of a messenger RNA (mRNA) vaccine and a cancer drug for the treatment of melanoma. Is mRNA set to shake up the world of cancer treatment? This is certainly what Moderna seems to think; the pharmaceutical company has...